Patents by Inventor Takuto Kojima
Takuto Kojima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190248776Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.Type: ApplicationFiled: April 25, 2019Publication date: August 15, 2019Inventors: Takahiro SUGIMOTO, Shinkichi SUZUKI, Hiroki SAKAMOTO, Masami YAMADA, Minoru NAKAMURA, Makoto KAMATA, Kenichiro SHIMOKAWA, Masaki OGINO, Eiji KIMURA, Masataka MURAKAMI, Jinichi YONEMORI, Takuto KOJIMA
-
Patent number: 10323027Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.Type: GrantFiled: June 23, 2016Date of Patent: June 18, 2019Assignee: Takeda Pharmaceutical Company LimitedInventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Masataka Murakami, Jinichi Yonemori, Takuto Kojima
-
Publication number: 20190169166Abstract: Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.Type: ApplicationFiled: August 9, 2017Publication date: June 6, 2019Applicant: Takeda Pharmaceutical Company LimitedInventors: Jun FUJIMOTO, Xin LIU, Osamu KURASAWA, Terufumi TAKAGI, Douglas Robert CARY, Hiroshi BANNO, Yasutomi ASANO, Takuto KOJIMA
-
Publication number: 20190135799Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: July 30, 2018Publication date: May 9, 2019Inventors: Masahiro ITO, Hideyuki SUGIYAMA, Osamu KUBO, Fumiaki KIKUCHI, Takeshi YASUI, Keiko KAKEGAWA, Zenichi IKEDA, Tohru MIYAZAKI, Yasuyoshi ARIKAWA, Tomohiro OKAWA, Jinichi YONEMORI, Akinori TOITA, Takuto KOJIMA, Yasutomi ASANO, Ayumu SATO, Hironobu MAEZAKI, Shinobu SASAKI, Hironori KOKUBO, Misaki HOMMA, Minoru SASAKI, Yasuhiro IMAEDA
-
Publication number: 20190106437Abstract: Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein.].Type: ApplicationFiled: April 27, 2017Publication date: April 11, 2019Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Youichi KAWAKITA, Takuto KOJIMA, Noriyuki NII, Yoshiteru ITO, Nobuki SAKAUCHI, Hiroshi BANNO, Xin LIU, Koji ONO, Keisuke IMAMURA, Shinichi IMAMURA
-
Publication number: 20190062274Abstract: The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).Type: ApplicationFiled: October 30, 2018Publication date: February 28, 2019Inventors: Yasutomi ASANO, Takuto KOJIMA, Osamu KURASAWA, Tzu-Tshin WONG, Yasuhiro HIRATA, Naoki IWAMURA, Bunnai SAITO, Yuta TANAKA, Ryosuke ARAI, Shinichi IMAMURA, Kazuko YONEMORI, Yasufumi MIYAMOTO, Shuji KITAMURA, Osamu SANO
-
Patent number: 10208046Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as medicaments such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) wherein ring A is an optionally substituted 5- or 6-membered ring; R is a C1-6 alkyl group substituted by 1 to 5 halogen atoms; and X is —CH? or —N?, or a salt thereof.Type: GrantFiled: May 15, 2015Date of Patent: February 19, 2019Assignee: Takeda Pharmaceutical Company LimitedInventors: Takahiro Sugimoto, Kenichiro Shimokawa, Takuto Kojima, Hiroki Sakamoto, Ikuo Fujimori, Minoru Nakamura, Masami Yamada, Masataka Murakami, Makoto Kamata, Shinkichi Suzuki
-
Patent number: 10189785Abstract: The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).Type: GrantFiled: April 19, 2016Date of Patent: January 29, 2019Assignee: Takeda Pharmaceuticals Company LimitedInventors: Yasutomi Asano, Takuto Kojima, Osamu Kurasawa, Tzu-Tshin Wong, Yasuhiro Hirata, Naoki Iwamura, Bunnai Saito, Yuta Tanaka, Ryosuke Arai, Shinichi Imamura, Kazuko Yonemori, Yasufumi Miyamoto, Shuji Kitamura, Osamu Sano
-
Publication number: 20180362516Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.Type: ApplicationFiled: August 27, 2018Publication date: December 20, 2018Inventors: Takahiro SUGIMOTO, Shinkichi SUZUKI, Hiroki SAKAMOTO, Masami YAMADA, Minoru NAKAMURA, Makoto KAMATA, Kenichiro SHIMOKAWA, Takuto KOJIMA
-
Publication number: 20180303841Abstract: The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.Type: ApplicationFiled: October 19, 2016Publication date: October 25, 2018Inventors: Takahiro SUGIMOTO, Shinkichi SUZUKI, Hiroki SAKAMOTO, Masami YAMADA, Minoru NAKAMURA, Makoto KAMATA, Kenichiro SHIMOKAWA, Masaki OGINO, Eiji KIMURA, Masataka MURAKAMI, Takuto KOJIMA, Jinichi YONEMORI
-
Patent number: 10087150Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.Type: GrantFiled: October 31, 2017Date of Patent: October 2, 2018Assignee: Takeda Pharmaceutical Company LimitedInventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Takuto Kojima
-
Patent number: 10053456Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.Type: GrantFiled: April 9, 2015Date of Patent: August 21, 2018Assignee: Takeda Pharmaceutical Company LimitedInventors: Shigemitsu Matsumoto, Yasushi Hattori, Masashi Toyofuku, Shinji Morimoto, Masaki Daini, Takuto Kojima, Tomohiro Kaku, Mitsuhiro Ito
-
Publication number: 20180170874Abstract: The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).Type: ApplicationFiled: April 19, 2016Publication date: June 21, 2018Inventors: Yasutomi ASANO, Takuto KOJIMA, Osamu KURASAWA, Tzu-Tshin WONG, Yasuhiro HIRATA, Naoki IWAMURA, Bunnai SAITO, Yuta TANAKA, Ryosuke ARAI, Shinichi IMAMURA, Kazuko YONEMORI, Yasufumi MIYAMOTO, Shuji KITAMURA, Osamu SANO
-
Publication number: 20180162853Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.Type: ApplicationFiled: January 29, 2018Publication date: June 14, 2018Inventors: Shigemitsu MATSUMOTO, Yasushi HATTORI, Masashi TOYOFUKU, Shinji MORIMOTO, Masaki DAINI, Takuto KOJIMA, Tomohiro KAKU, Mitsuhiro ITO
-
Publication number: 20180162850Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.Type: ApplicationFiled: June 23, 2016Publication date: June 14, 2018Inventors: Takahiro SUGIMOTO, Shinkichi SUZUKI, Hiroki SAKAMOTO, Masami YAMADA, Minoru NAKAMURA, Makoto KAMATA, Kenichiro SHIMOKAWA, Masaki OGINO, Eiji KIMURA, Masataka MURAKAMI, Jinichi YONEMORI, Takuto KOJIMA
-
Patent number: 9920047Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.Type: GrantFiled: September 20, 2016Date of Patent: March 20, 2018Assignee: Takeda Pharmaceutical Company LimitedInventors: Shigemitsu Matsumoto, Yasushi Hattori, Masashi Toyofuku, Shinji Morimoto, Masaki Daini, Takuto Kojima, Tomohiro Kaku, Mitsuhiro Ito
-
Publication number: 20180050996Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.Type: ApplicationFiled: October 31, 2017Publication date: February 22, 2018Inventors: Takahiro SUGIMOTO, Shinkichi SUZUKI, Hiroki SAKAMOTO, Masami YAMADA, Minoru NAKAMURA, Makoto KAMATA, Kenichiro SHIMOKAWA, Takuto KOJIMA
-
Patent number: 9878989Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.Type: GrantFiled: June 23, 2016Date of Patent: January 30, 2018Assignee: Takeda Pharmaceutical Company LimitedInventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Masataka Murakami, Jinichi Yonemori, Takuto Kojima
-
Patent number: 9777005Abstract: Provided is a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, and useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder and the like. The present invention relates to a compound represented by the formula wherein ring A is a 4- to 7-membered ring optionally having substituent(s); L is —O—, —S—, —SO— or —SO2—; R1 is a C1-6 alkyl group optionally having substituent(s) (provided that when L is —O—, R1 is not a C1-6 alkyl group optionally substituted by halogen atom(s)), or a cyclic group optionally having substituent(s); X1 is —CRa? or —N?; X2 is —CRb? or —N?; X3 is —CRc= or —N?; Ra, Rb and Rc are each a C1-6 alkyl group, C2-6 alkenyl group, C1-6 alkoxy group, C3-6 cycloalkyl group, C3-6 cycloalkoxy group or C6-14 aryl group, each of which optionally having substituent(s), H or halogen, or a salt thereof.Type: GrantFiled: November 18, 2013Date of Patent: October 3, 2017Assignee: Takeda Pharmaceutical Company LimitedInventors: Takahiro Sugimoto, Minoru Nakamura, Hiroki Sakamoto, Shinkichi Suzuki, Masami Yamada, Makoto Kamata, Takuto Kojima, Ikuo Fujimori, Kenichiro Shimokawa
-
Patent number: 9751885Abstract: The present invention provides a compound having a lysine specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, Alzheimer's disease, Parkinson's disease or Huntington's disease, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); B is a benzene ring optionally having further substituent(s); R1, R2 and R3 are each independently a hydrogen atom, a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); A and R1 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s); and R2 and R3 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s), or a salt thereof.Type: GrantFiled: October 11, 2013Date of Patent: September 5, 2017Assignee: Takeda Pharmaceutical Company LimitedInventors: Naoki Tomita, Daisuke Tomita, Yusuke Tominari, Shinichi Imamura, Shinji Morimoto, Takuto Kojima, Masashi Toyofuku, Yasushi Hattori, Tomohiro Kaku, Mitsuhiro Ito